1
|
McKenzie C, Bucks RS, Weinborn M, Bourgeat P, Salvado O, Gavett BE. Tau and amyloid biomarkers modify the degree to which cognitive reserve and brain reserve predict cognitive decline. J Int Neuropsychol Soc 2023; 29:572-581. [PMID: 36039968 DOI: 10.1017/s1355617722000546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Brain reserve, cognitive reserve, and education are thought to protect against late-life cognitive decline, but these variables have not been directly compared to one another in the same model, using future cognitive and functional decline as outcomes. We sought to determine whether the influence of these protective factors on executive function (EF) and daily function decline was dependent upon Alzheimer's disease (AD) pathology severity, as measured by the total tau to beta-amyloid (T-τ/Aβ1-42) ratio in cerebrospinal fluid (CSF). METHOD Participants were 1201 older adult volunteers in the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. Brain reserve was defined using a composite index of structural brain volumes (total brain matter, hippocampus, and white matter hyperintensity). Cognitive reserve was defined as the variance in episodic memory performance not explained by brain integrity and demographics. RESULTS At higher levels of T-τ/Aβ1-42, brain and cognitive reserve predicted slower decline in EF. Only brain reserve attenuated decline at lower levels of T-τ/Aβ1-42. Education had no independent association with cognitive decline. CONCLUSIONS These results point to a hierarchy of protection against aging- and disease-associated cognitive decline. When pathology is low, only structural brain integrity predicts rate of future EF decline. The ability of cognitive reserve to predict future EF decline becomes stronger as CSF biomarker evidence of AD increases. Although education is typically thought of as a proxy for cognitive reserve, it did not show any protective effects on cognition after accounting for brain integrity and the residual cognitive reserve index.
Collapse
Affiliation(s)
- Cathryn McKenzie
- School of Psychological Science, The University of Western Australia, Perth, WA, 6009, Australia
| | - Romola S Bucks
- School of Psychological Science, The University of Western Australia, Perth, WA, 6009, Australia
| | - Michael Weinborn
- School of Psychological Science, The University of Western Australia, Perth, WA, 6009, Australia
| | - Pierrick Bourgeat
- Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, QLD, 4006, Australia
| | | | - Brandon E Gavett
- School of Psychological Science, The University of Western Australia, Perth, WA, 6009, Australia
| |
Collapse
|
2
|
McKenzie C, Bucks RS, Weinborn M, Bourgeat P, Salvado O, Gavett BE. Residual reserve index modifies the effect of amyloid pathology on FDG metabolism: implications for efficiency and capacity in cognitive reserve. Alzheimers Dement 2022. [DOI: 10.1002/alz.066376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Cathryn McKenzie
- University of Western Australia Perth Western Australia Australia
| | - Romola S Bucks
- University of Western Australia Perth Western Australia Australia
| | - Michael Weinborn
- University of Western Australia Perth Western Australia Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | | | - Brandon E Gavett
- University of Western Australia Perth Western Australia Australia
| |
Collapse
|
3
|
McKenzie C, Bucks RS, Weinborn M, Bourgeat P, Salvado O, Gavett BE. Residual reserve index modifies the effect of amyloid pathology on fluorodeoxyglucose metabolism: Implications for efficiency and capacity in cognitive reserve. Front Aging Neurosci 2022; 14:943823. [PMID: 36034126 PMCID: PMC9413056 DOI: 10.3389/fnagi.2022.943823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Accepted: 07/25/2022] [Indexed: 11/13/2022] Open
Abstract
Background The residual approach to measuring cognitive reserve (using the residual reserve index) aims to capture cognitive resilience conferred by cognitive reserve, but may be confounded by factors representing brain resilience. We sought to distinguish between brain and cognitive resilience by comparing interactions between the residual reserve index and amyloid, tau, and neurodegeneration [“AT(N)”] biomarkers when predicting executive function. We hypothesized that the residual reserve index would moderate at least one path from an AT(N) biomarker to executive function (consistent with cognitive resilience), as opposed to moderating a path between two AT(N) biomarkers (suggestive of brain resilience). Methods Participants (N = 332) were from the Alzheimer’s Disease Neuroimaging Initiative. The residual reserve index represented the difference between observed and predicted memory performance (a positive residual reserve index suggests higher cognitive reserve). AT(N) biomarkers were: CSF β-amyloid1–42/β-amyloid1–40 (A), plasma phosphorylated tau-181 (T), and FDG metabolism in AD-specific regions ([N]). AT(N) biomarkers (measured at consecutive time points) were entered in a sequential mediation model testing the indirect effects from baseline amyloid to executive function intercept (third annual follow-up) and slope (baseline to seventh follow-up), via tau and/or FDG metabolism. The baseline residual reserve index was entered as a moderator of paths between AT(N) biomarkers (e.g., amyloid-tau), and paths between AT(N) biomarkers and executive function. Results The residual reserve index interacted with amyloid pathology when predicting FDG metabolism: the indirect effect of amyloid → FDG metabolism → executive function intercept and slope varied as a function of the residual reserve index. With lower amyloid pathology, executive function performance was comparable at different levels of the residual reserve index, but a higher residual reserve index was associated with lower FDG metabolism. With higher amyloid pathology, a higher residual reserve index predicted better executive function via higher FDG metabolism. Conclusion The effect of the residual reserve index on executive function performance via FDG metabolism was consistent with cognitive resilience. This suggests the residual reserve index captures variation in cognitive reserve; specifically, neural efficiency, and neural capacity to upregulate metabolism to enhance cognitive resilience in the face of greater amyloid pathology. Implications for future research include the potential bidirectionality between neural efficiency and amyloid accumulation.
Collapse
Affiliation(s)
- Cathryn McKenzie
- School of Psychological Science, The University of Western Australia, Perth, WA, Australia
- *Correspondence: Cathryn McKenzie,
| | - Romola S. Bucks
- School of Psychological Science, The University of Western Australia, Perth, WA, Australia
| | - Michael Weinborn
- School of Psychological Science, The University of Western Australia, Perth, WA, Australia
| | - Pierrick Bourgeat
- Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation (CSIRO) Health and Biosecurity, Brisbane, QLD, Australia
| | - Olivier Salvado
- Data61, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Sydney, NSW, Australia
| | - Brandon E. Gavett
- School of Psychological Science, The University of Western Australia, Perth, WA, Australia
| |
Collapse
|
4
|
Momeni S, Fazlollahi A, Lebrat L, Yates P, Rowe C, Gao Y, Liew AWC, Salvado O. Generative Model of Brain Microbleeds for MRI Detection of Vascular Marker of Neurodegenerative Diseases. Front Neurosci 2022; 15:778767. [PMID: 34975381 PMCID: PMC8716785 DOI: 10.3389/fnins.2021.778767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 11/05/2021] [Indexed: 11/13/2022] Open
Abstract
Cerebral microbleeds (CMB) are increasingly present with aging and can reveal vascular pathologies associated with neurodegeneration. Deep learning-based classifiers can detect and quantify CMB from MRI, such as susceptibility imaging, but are challenging to train because of the limited availability of ground truth and many confounding imaging features, such as vessels or infarcts. In this study, we present a novel generative adversarial network (GAN) that has been trained to generate three-dimensional lesions, conditioned by volume and location. This allows one to investigate CMB characteristics and create large training datasets for deep learning-based detectors. We demonstrate the benefit of this approach by achieving state-of-the-art CMB detection of real CMB using a convolutional neural network classifier trained on synthetic CMB. Moreover, we showed that our proposed 3D lesion GAN model can be applied on unseen dataset, with different MRI parameters and diseases, to generate synthetic lesions with high diversity and without needing laboriously marked ground truth.
Collapse
Affiliation(s)
- Saba Momeni
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Data61, Brisbane, QLD, Australia.,School of Engineering and Built Environment, Griffith University, Nathan, QLD, Australia
| | - Amir Fazlollahi
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Health and Biosecurity, Australian E-Health Research Centre, Brisbane, QLD, Australia.,Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - Leo Lebrat
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Health and Biosecurity, Australian E-Health Research Centre, Brisbane, QLD, Australia
| | - Paul Yates
- Department of Geriatric Medicine, Austin Health, Heidelberg, VIC, Australia
| | - Christopher Rowe
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.,The Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Yongsheng Gao
- School of Engineering and Built Environment, Griffith University, Nathan, QLD, Australia
| | - Alan Wee-Chung Liew
- School of Information and Communication Technology, Griffith University, Nathan, QLD, Australia
| | - Olivier Salvado
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) Data61, Brisbane, QLD, Australia.,Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, VIC, Australia
| |
Collapse
|
5
|
Xia Y, Fazlollahi A, Dore V, Bourgeat P, Raniga P, Martin N, Salvado O, Rose S, Lupton MK, Breakspear M, Fripp J. Accumulation of amyloid‐β alters white matter integrity in cognitively unimpaired middle‐aged females. Alzheimers Dement 2021. [DOI: 10.1002/alz.053113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Ying Xia
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane QLD Australia
| | - Amir Fazlollahi
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane QLD Australia
| | - Vincent Dore
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Parkville VIC Australia
- Austin Health Melbourne VIC Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane QLD Australia
| | - Parnesh Raniga
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane QLD Australia
| | - Nick Martin
- QIMR Berghofer Medical Research Institute Brisbane QLD Australia
| | | | - Stephen Rose
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane QLD Australia
| | | | - Michael Breakspear
- QIMR Berghofer Medical Research Institute Brisbane QLD Australia
- The University of Newcastle Newcastle NSW Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane QLD Australia
| | | |
Collapse
|
6
|
Xia Y, Yassi N, Raniga P, Bourgeat P, Desmond P, Doecke J, Ames D, Laws SM, Fowler C, Rainey-Smith SR, Martins R, Maruff P, Villemagne VL, Masters CL, Rowe CC, Fripp J, Salvado O. Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. J Alzheimers Dis 2021; 78:321-334. [PMID: 32986666 DOI: 10.3233/jad-200419] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
BACKGROUND Cerebrovascular disease often coexists with Alzheimer's disease (AD). While both diseases share common risk factors, their interrelationship remains unclear. Increasing the understanding of how cerebrovascular changes interact with AD is essential to develop therapeutic strategies and refine biomarkers for early diagnosis. OBJECTIVE We investigate the prevalence and risk factors for the comorbidity of amyloid-β (Aβ) and cerebrovascular disease in the Australian Imaging, Biomarkers and Lifestyle Study of Ageing, and further examine their cross-sectional association. METHODS A total of 598 participants (422 cognitively normal, 89 with mild cognitive impairment, 87 with AD) underwent positron emission tomography and structural magnetic resonance imaging for assessment of Aβ deposition and cerebrovascular disease. Individuals were categorized based on the comorbidity status of Aβ and cerebrovascular disease (V) as Aβ-V-, Aβ-V+, Aβ+V-, or Aβ+V+. RESULTS Advancing age was associated with greater likelihood of cerebrovascular disease, high Aβ load and their comorbidity. Apolipoprotein E ɛ4 carriage was only associated with Aβ positivity. Greater total and regional WMH burden were observed in participants with AD. However, no association were observed between Aβ and WMH measures after stratification by clinical classification, suggesting that the observed association between AD and cerebrovascular disease was driven by the common risk factor of age. CONCLUSION Our observations demonstrate common comorbid condition of Aβ and cerebrovascular disease in later life. While our study did not demonstrate a convincing cross-sectional association between Aβ and WMH burden, future longitudinal studies are required to further confirm this.
Collapse
Affiliation(s)
- Ying Xia
- The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, QLD, Australia
| | - Nawaf Yassi
- Department of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.,Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.,The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
| | - Parnesh Raniga
- The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, QLD, Australia
| | - Pierrick Bourgeat
- The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, QLD, Australia
| | - Patricia Desmond
- Department of Radiology, The Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia
| | - James Doecke
- The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, QLD, Australia
| | - David Ames
- National Ageing Research Institute, Parkville, VIC, Australia.,Academic Unit for Psychiatry of Old Age, University of Melbourne, Parkville, VIC, Australia
| | - Simon M Laws
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, WA, Australia
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
| | - Stephanie R Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, WA, Australia
| | - Ralph Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, WA, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.,Cog State Ltd, Melbourne, VIC, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.,Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.,Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
| | - Christopher C Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.,Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia
| | - Jurgen Fripp
- The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, QLD, Australia
| | - Olivier Salvado
- The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, QLD, Australia.,CSIRO Data61, Brisbane, QLD, Australia
| | | |
Collapse
|
7
|
Momeni S, Fazlollahi A, Yates P, Rowe C, Gao Y, Liew AWC, Salvado O. Synthetic microbleeds generation for classifier training without ground truth. Comput Methods Programs Biomed 2021; 207:106127. [PMID: 34051412 DOI: 10.1016/j.cmpb.2021.106127] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Accepted: 04/21/2021] [Indexed: 06/12/2023]
Abstract
BACKGROUND AND OBJECTIVE Cerebral microbleeds (CMB) are important biomarkers of cerebrovascular diseases and cognitive dysfunctions. Susceptibility weighted imaging (SWI) is a common MRI sequence where CMB appear as small hypointense blobs. The prevalence of CMB in the population and in each scan is low, resulting in tedious and time-consuming visual assessment. Automated detection methods would be of value but are challenged by the CMB low prevalence, the presence of mimics such as blood vessels, and the difficulty to obtain sufficient ground truth for training and testing. In this paper, synthetic CMB (sCMB) generation using an analytical model is proposed for training and testing machine learning methods. The main aim is creating perfect synthetic ground truth as similar as reals, in high number, with a high diversity of shape, volume, intensity, and location to improve training of supervised methods. METHOD sCMB were modelled with a random Gaussian shape and added to healthy brain locations. We compared training on our synthetic data to standard augmentation techniques. We performed a validation experiment using sCMB and report result for whole brain detection using a 10-fold cross validation design with an ensemble of 10 neural networks. RESULTS Performance was close to state of the art (~9 false positives per scan), when random forest was trained on synthetic only and tested on real lesion. Other experiments showed that top detection performance could be achieved when training on synthetic CMB only. Our dataset is made available, including a version with 37,000 synthetic lesions, that could be used for benchmarking and training. CONCLUSION Our proposed synthetic microbleeds model is a powerful data augmentation approach for CMB classification with and should be considered for training automated lesion detection system from MRI SWI.
Collapse
Affiliation(s)
- Saba Momeni
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia; School of Engineering and Built Environment, Griffith University, Brisbane, Australia.
| | - Amir Fazlollahi
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | - Paul Yates
- Department of Aged Care, Austin Health, Heidelberg, Victoria, Australia
| | - Christopher Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia
| | - Yongsheng Gao
- School of Engineering and Built Environment, Griffith University, Brisbane, Australia
| | - Alan Wee-Chung Liew
- School of Information & Communication Technology, Griffith University, Gold Coast, Australia
| | | |
Collapse
|
8
|
Fowler C, Rainey-Smith SR, Bird S, Bomke J, Bourgeat P, Brown BM, Burnham SC, Bush AI, Chadunow C, Collins S, Doecke J, Doré V, Ellis KA, Evered L, Fazlollahi A, Fripp J, Gardener SL, Gibson S, Grenfell R, Harrison E, Head R, Jin L, Kamer A, Lamb F, Lautenschlager NT, Laws SM, Li QX, Lim L, Lim YY, Louey A, Macaulay SL, Mackintosh L, Martins RN, Maruff P, Masters CL, McBride S, Milicic L, Peretti M, Pertile K, Porter T, Radler M, Rembach A, Robertson J, Rodrigues M, Rowe CC, Rumble R, Salvado O, Savage G, Silbert B, Soh M, Sohrabi HR, Taddei K, Taddei T, Thai C, Trounson B, Tyrrell R, Vacher M, Varghese S, Villemagne VL, Weinborn M, Woodward M, Xia Y, Ames D. Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. J Alzheimers Dis Rep 2021; 5:443-468. [PMID: 34368630 PMCID: PMC8293663 DOI: 10.3233/adr-210005] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in 2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild cognitive impairment (MCI), and 211 with Alzheimer’s disease dementia (AD)) as an ‘Inception cohort’ who underwent detailed ssessments every 18 months. Over the past decade, an additional 1247 subjects have been added as an ‘Enrichment cohort’ (as of 10 April 2019). Objective: Here we provide an overview of these Inception and Enrichment cohorts of more than 8,500 person-years of investigation. Methods: Participants underwent reassessment every 18 months including comprehensive cognitive testing, neuroimaging (magnetic resonance imaging, MRI; positron emission tomography, PET), biofluid biomarkers and lifestyle evaluations. Results: AIBL has made major contributions to the understanding of the natural history of AD, with cognitive and biological definitions of its three major stages: preclinical, prodromal and clinical. Early deployment of Aβ-amyloid and tau molecular PET imaging and the development of more sensitive and specific blood tests have facilitated the assessment of genetic and environmental factors which affect age at onset and rates of progression. Conclusion: This fifteen-year study provides a large database of highly characterized individuals with longitudinal cognitive, imaging and lifestyle data and biofluid collections, to aid in the development of interventions to delay onset, prevent or treat AD. Harmonization with similar large longitudinal cohort studies is underway to further these aims.
Collapse
Affiliation(s)
- Christopher Fowler
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Stephanie R Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.,School of Psychological Science, University of Western Australia, Crawley, WA, Australia
| | - Sabine Bird
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Julia Bomke
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Pierrick Bourgeat
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Belinda M Brown
- Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia
| | - Samantha C Burnham
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Ashley I Bush
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Carolyn Chadunow
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Steven Collins
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - James Doecke
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia.,Cooperative Research Council for Mental Health, Melbourne, VIC, Australia
| | - Vincent Doré
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia.,Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Kathryn A Ellis
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia.,University of Melbourne Academic Unit for Psychiatry of Old Age, Parkville, VIC, Australia.,Melbourne School of Psychological Sciences, Melbourne, VIC, Australia
| | - Lis Evered
- Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC, Australia
| | - Amir Fazlollahi
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Jurgen Fripp
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Samantha L Gardener
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Simon Gibson
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Robert Grenfell
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Elise Harrison
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Richard Head
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Liang Jin
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Adrian Kamer
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Fiona Lamb
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
| | | | - Simon M Laws
- Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| | - Qiao-Xin Li
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Lucy Lim
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Yen Ying Lim
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia.,Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, VIC, Australia
| | - Andrea Louey
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - S Lance Macaulay
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Lucy Mackintosh
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | | | - Colin L Masters
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Simon McBride
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Lidija Milicic
- Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Madeline Peretti
- Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Kelly Pertile
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Tenielle Porter
- Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| | - Morgan Radler
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Alan Rembach
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Joanne Robertson
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Mark Rodrigues
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Rebecca Rumble
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | | | - Greg Savage
- Department of Psychology, Macquarie University, Sydney, NSW, Australia
| | - Brendan Silbert
- Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC, Australia
| | - Magdalene Soh
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Hamid R Sohrabi
- Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.,Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | - Kevin Taddei
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Tania Taddei
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Christine Thai
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Brett Trounson
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Regan Tyrrell
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Michael Vacher
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Shiji Varghese
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Victor L Villemagne
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.,Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,School of Psychological Science, University of Western Australia, Crawley, WA, Australia
| | - Michael Woodward
- Department of Geriatric Medicine Austin Hospital, Heidelberg, VIC, Australia
| | - Ying Xia
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - David Ames
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia.,University of Melbourne Academic Unit for Psychiatry of Old Age, Parkville, VIC, Australia.,National Ageing Research Institute (NARI), Parkville, VIC, Australia
| | | |
Collapse
|
9
|
Gardener SL, Weinborn M, Sohrabi HR, Doecke JD, Bourgeat P, Rainey-Smith SR, Shen KK, Fripp J, Taddei K, Maruff P, Salvado O, Savage G, Ames D, Masters CL, Rowe CC, Martins RN. Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. J Alzheimers Dis 2021; 81:1039-1052. [PMID: 33935071 PMCID: PMC8293653 DOI: 10.3233/jad-201243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: Previous research has identified a small subgroup of older adults that maintain a high level of cognitive functioning well into advanced age. Investigation of those with superior cognitive performance (SCP) for their age is important, as age-related decline has previously been thought to be inevitable. Objective: Preservation of cortical thickness and volume was evaluated in 76 older adults with SCP and 100 typical older adults (TOAs) assessed up to five times over six years. Methods: Regions of interest (ROIs) found to have been associated with super-aging status (a construct similar to SCP status) in previous literature were investigated, followed by a discovery phase analyses of additional regions. SCPs were aged 70 + at baseline, scoring at/above normative memory (CVLT-II) levels for demographically similar individuals aged 30–44 years old, and in the unimpaired range for all other cognitive domains over the course of the study. Results: In linear mixed models, following adjustment for multiple comparisons, there were no significant differences between rates of thinning or volume atrophy between SCPs and TOAs in previously identified ROIs, or the discovery phase analyses. With only amyloid-β negative individuals in the analyses, again there were no significant differences between SCPs and TOAs. Conclusion: The increased methodological rigor in classifying groups, together with the influence of cognitive reserve, are discussed as potential factors accounting for our findings as compared to the extant literature on those with superior cognitive performance for their age.
Collapse
Affiliation(s)
- Samantha L Gardener
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia
| | - Hamid R Sohrabi
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,College of Science, Health, Engineering and Education, Murdoch University, Murdoch, Western Australia, Australia.,Department of Biomedical Sciences, Macquarie University, New South Wales, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia
| | - Stephanie R Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia.,Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia
| | - Kai-Kai Shen
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia
| | - Kevin Taddei
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia
| | - Paul Maruff
- CogState, Ltd., Melbourne, Victoria, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia.,CSIRO Data61, Sydney, Australia
| | - Greg Savage
- ARC Centre of Excellence in Cognition and its Disorders and Department of Psychology, Macquarie University, New South Wales, Australia
| | - David Ames
- National Ageing Research Institute, Royal Melbourne Hospital, Melbourne, Australia.,Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia.,Florey Department of the University of Melbourne
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,Department of Biomedical Sciences, Macquarie University, New South Wales, Australia
| | | |
Collapse
|
10
|
Fernandez S, Burnham SC, Milicic L, Savage G, Maruff P, Peretti M, Sohrabi HR, Lim YY, Weinborn M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Porter T, Laws SM. SPON1 Is Associated with Amyloid-β and APOE ε4-Related Cognitive Decline in Cognitively Normal Adults. J Alzheimers Dis Rep 2021; 5:111-120. [PMID: 33782664 PMCID: PMC7990462 DOI: 10.3233/adr-200246] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Abstract.
Collapse
Affiliation(s)
- Shane Fernandez
- Australian Alzheimer's Research Foundation, Nedlands, Western Australia.,Collaborative Genomics and Translation Group, Center for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Samantha C Burnham
- Collaborative Genomics and Translation Group, Center for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,CSIRO Health and Biosecurity, Parkville, Victoria, Australia
| | - Lidija Milicic
- Collaborative Genomics and Translation Group, Center for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Greg Savage
- ARC Centre of Excellence in Cognition and its Disorders, Department of Psychology, Macquarie University, North Ryde, NSW, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.,CogState Ltd., Melbourne, Victoria, Australia
| | - Madeline Peretti
- Collaborative Genomics and Translation Group, Center for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Hamid R Sohrabi
- Australian Alzheimer's Research Foundation, Nedlands, Western Australia.,Centre for Healthy Ageing, Murdoch University, Murdoch, Western Australia, Australia.,Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.,Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Yen Ying Lim
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia
| | - Michael Weinborn
- Australian Alzheimer's Research Foundation, Nedlands, Western Australia.,Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, Victoria, Australia.,National Ageing Research Institute, Parkville, Victoria, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Ralph N Martins
- Australian Alzheimer's Research Foundation, Nedlands, Western Australia.,Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.,Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Stephanie Rainey-Smith
- Australian Alzheimer's Research Foundation, Nedlands, Western Australia.,Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Christopher C Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity/Australian e-Health Research Centre, Herston, Queensland, Australia
| | - David Groth
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | - Giuseppe Verdile
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | - Victor L Villemagne
- Collaborative Genomics and Translation Group, Center for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Tenielle Porter
- Collaborative Genomics and Translation Group, Center for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | - Simon M Laws
- Collaborative Genomics and Translation Group, Center for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| |
Collapse
|
11
|
Lupton MK, Robinson GA, Adam RJ, Rose S, Byrne GJ, Salvado O, Pachana NA, Almeida OP, McAloney K, Gordon SD, Raniga P, Fazlollahi A, Xia Y, Ceslis A, Sonkusare S, Zhang Q, Kholghi M, Karunanithi M, Mosley PE, Lv J, Borne L, Adsett J, Garden N, Fripp J, Martin NG, Guo CC, Breakspear M. A prospective cohort study of prodromal Alzheimer's disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA). Neuroimage Clin 2020; 29:102527. [PMID: 33341723 PMCID: PMC7750170 DOI: 10.1016/j.nicl.2020.102527] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Revised: 11/11/2020] [Accepted: 12/04/2020] [Indexed: 12/20/2022]
Abstract
This prospective cohort study, "Prospective Imaging Study of Ageing: Genes, Brain and Behaviour" (PISA) seeks to characterise the phenotype and natural history of healthy adult Australians at high future risk of Alzheimer's disease (AD). In particular, we are recruiting midlife and older Australians with high and low genetic risk of dementia to discover biological markers of early neuropathology, identify modifiable risk factors, and establish the very earliest phenotypic and neuronal signs of disease onset. PISA utilises genetic prediction to recruit and enrich a prospective cohort and follow them longitudinally. Online surveys and cognitive testing are used to characterise an Australia-wide sample currently totalling over 3800 participants. Participants from a defined at-risk cohort and positive controls (clinical cohort of patients with mild cognitive impairment or early AD) are invited for onsite visits for detailed functional, structural and molecular neuroimaging, lifestyle monitoring, detailed neurocognitive testing, plus blood sample donation. This paper describes recruitment of the PISA cohort, study methodology and baseline demographics.
Collapse
Affiliation(s)
| | - Gail A Robinson
- School of Psychology, The University of Queensland, St. Lucia, Brisbane, Australia; Queensland Brain Institute, The University of Queensland, St. Lucia, Brisbane, Australia
| | - Robert J Adam
- QIMR Berghofer Medical Research Institute, Brisbane, Australia; Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane, Australia; Royal Brisbane and Women's Hospital Mental Health Services, University of Queensland, Brisbane, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - Stephen Rose
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | - Gerard J Byrne
- Royal Brisbane and Women's Hospital Mental Health Services, University of Queensland, Brisbane, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | - Nancy A Pachana
- School of Psychology, The University of Queensland, St. Lucia, Brisbane, Australia
| | - Osvaldo P Almeida
- Medical School, University of Western Australia, Perth, Australia; WA Centre for Health and Ageing of the University of Western Australia, Australia
| | - Kerrie McAloney
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Scott D Gordon
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Parnesh Raniga
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | - Amir Fazlollahi
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | - Ying Xia
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | - Amelia Ceslis
- School of Psychology, The University of Queensland, St. Lucia, Brisbane, Australia
| | | | - Qing Zhang
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | - Mahnoosh Kholghi
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | - Mohan Karunanithi
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | - Philip E Mosley
- QIMR Berghofer Medical Research Institute, Brisbane, Australia; Queensland Brain Institute, The University of Queensland, St. Lucia, Brisbane, Australia; Neurosciences Queensland, Brisbane, Queensland, Australia
| | - Jinglei Lv
- Sydney Imaging & School of Biomedical Engineering, The University of Sydney, Sydney, Australia
| | - Léonie Borne
- The University of Newcastle, Newcastle, Australia
| | - Jessica Adsett
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Natalie Garden
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
| | | | - Christine C Guo
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Michael Breakspear
- QIMR Berghofer Medical Research Institute, Brisbane, Australia; The University of Newcastle, Newcastle, Australia
| |
Collapse
|
12
|
Ayton S, Woodward M, Ellis KA, Lim YY, Maruff PT, Desmond PM, Salvado O, Fazlollahi A, Rowe CC, Churilov L, Bush AI. Deferiprone to delay dementia (the 3D trial). Alzheimers Dement 2020. [DOI: 10.1002/alz.044107] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Scott Ayton
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | | | | | - Yen Ying Lim
- Washington University in St. Louis St. Louis MO USA
| | | | - Patricia M. Desmond
- Royal Melbourne Hospital The University of Melbourne Melbourne VIC Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane QLD Australia
| | - Amir Fazlollahi
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane QLD Australia
| | | | | | | | | |
Collapse
|
13
|
Lupton MK, Fazlollahi A, Ceslis A, Fripp J, Rose S, Salvado O, Robinson G, Guo C, Breakspear M, Martin N. The use of genetic risk prediction to study prodromal Alzheimer’s disease in the PISA study. Alzheimers Dement 2020. [DOI: 10.1002/alz.045023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | - Amir Fazlollahi
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | | | - Jurgen Fripp
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Stephen Rose
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | | | - Christine Guo
- QIMR Berghofer Medical Research Institute Brisbane Australia
| | | | - Nick Martin
- QIMR Berghofer Medical Research Institute Brisbane Australia
| |
Collapse
|
14
|
Xia Y, Fazlollahi A, Yates PA, Yassi N, Desmond PM, Salvado O, Villemagne VL, Rowe CC, Fripp J, Masters CL, Raniga P. Amyloid angiopathy may contribute to white‐matter hyperintensities in Alzheimer’s disease. Alzheimers Dement 2020. [DOI: 10.1002/alz.038899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Ying Xia
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Amir Fazlollahi
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Paul A. Yates
- The Florey Institute of Neuroscience and Mental Health Melbourne Australia
- Department of Medicine The University of Melbourne Melbourne Australia
- Department of Aged Care Austin Health Heidelberg Australia
| | - Nawaf Yassi
- The Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Australia
- Royal Melbourne Hospital The University of Melbourne Parkville Australia
- The Walter and Eliza Hall Institute of Medical Research Parkville Australia
| | | | - Olivier Salvado
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Victor L.L. Villemagne
- Department of Molecular Imaging and Therapy Austin Health Melbourne Australia
- Department of Medicine The University of Melbourne Austin Health Melbourne Australia
| | - Christopher C. Rowe
- The Florey Institute of Neuroscience and Mental Health Melbourne Australia
- Department of Molecular Imaging and Therapy Austin Health Melbourne Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health Melbourne Australia
| | - Parnesh Raniga
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| |
Collapse
|
15
|
Fazlollahi A, Raniga P, Bourgeat P, Yates PA, Bush AI, Salvado O, Ayton S. Limited cerebral microbleeds effect on regional magnetic susceptibility measured by MRI. Alzheimers Dement 2020. [DOI: 10.1002/alz.044125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Amir Fazlollahi
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Parnesh Raniga
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Paul A Yates
- Department of Medicine The University of Melbourne Melbourne Australia
- Department of Aged Care Austin Health Heidelberg Australia
| | - Ashley I Bush
- The University of Melbourne Melbourne Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne Australia
- Melbourne Dementia Research Centre Melbourne Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity Australian E‐Health Research Centre Brisbane Australia
| | - Scott Ayton
- The University of Melbourne Melbourne Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne Australia
- Melbourne Dementia Research Centre Melbourne Australia
| |
Collapse
|
16
|
van der Kall LM, Truong T, Burnham SC, Doré V, Mulligan RS, Bozinovski S, Lamb F, Bourgeat P, Fripp J, Schultz S, Lim YY, Laws SM, Ames D, Fowler C, Rainey-Smith SR, Martins RN, Salvado O, Robertson J, Maruff P, Masters CL, Villemagne VL, Rowe CC. Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. Neurology 2020; 96:e662-e670. [PMID: 33184233 PMCID: PMC7884996 DOI: 10.1212/wnl.0000000000011222] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Accepted: 09/24/2020] [Indexed: 02/04/2023] Open
Abstract
OBJECTIVE To determine the effect of β-amyloid (Aβ) level on progression risk to mild cognitive impairment (MCI) or dementia and longitudinal cognitive change in cognitively normal (CN) older individuals. METHODS All CN from the Australian Imaging Biomarkers and Lifestyle study with Aβ PET and ≥3 years follow-up were included (n = 534; age 72 ± 6 years; 27% Aβ positive; follow-up 5.3 ± 1.7 years). Aβ level was divided using the standardized 0-100 Centiloid scale: <15 CL negative, 15-25 CL uncertain, 26-50 CL moderate, 51-100 CL high, >100 CL very high, noting >25 CL approximates a positive scan. Cox proportional hazards analysis and linear mixed effect models were used to assess risk of progression and cognitive decline. RESULTS Aβ levels in 63% were negative, 10% uncertain, 10% moderate, 14% high, and 3% very high. Fifty-seven (11%) progressed to MCI or dementia. Compared to negative Aβ, the hazard ratio for progression for moderate Aβ was 3.2 (95% confidence interval [CI] 1.3-7.6; p < 0.05), for high was 7.0 (95% CI 3.7-13.3; p < 0.001), and for very high was 11.4 (95% CI 5.1-25.8; p < 0.001). Decline in cognitive composite score was minimal in the moderate group (-0.02 SD/year, p = 0.05), while the high and very high declined substantially (high -0.08 SD/year, p < 0.001; very high -0.35 SD/year, p < 0.001). CONCLUSION The risk of MCI or dementia over 5 years in older CN is related to Aβ level on PET, 5% if negative vs 25% if positive but ranging from 12% if 26-50 CL to 28% if 51-100 CL and 50% if >100 CL. This information may be useful for dementia risk counseling and aid design of preclinical AD trials.
Collapse
Affiliation(s)
- Laura M van der Kall
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Thanh Truong
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Samantha C Burnham
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Vincent Doré
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Rachel S Mulligan
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Svetlana Bozinovski
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Fiona Lamb
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Pierrick Bourgeat
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Jurgen Fripp
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Stephanie Schultz
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Yen Y Lim
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Simon M Laws
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - David Ames
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Christopher Fowler
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Stephanie R Rainey-Smith
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Ralph N Martins
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Olivier Salvado
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Joanne Robertson
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Paul Maruff
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Colin L Masters
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Victor L Villemagne
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO
| | - Christopher C Rowe
- From Austin Health (L.M.v.d.K., T.T., V.D., R.S.M., S.B., F.L., S.S., V.L.V., C.C.R.); CSIRO (S.C.B., V.D.), Melbourne; CSIRO (P.B., J.F., O.S.), Brisbane; The Florey Institute of Neuroscience and Mental Health (Y.Y.L., C.F., J.R., P.M., C.L.M.), Melbourne; University of Melbourne (T.T., D.A., C.L.M., V.L.V., C.C.R.); Edith Cowan University (S.M.L., S.R.R.-S., R.N.M.), Perth, Australia; and Washington University (S.S.), St. Louis, MO.
| |
Collapse
|
17
|
Mito R, Dhollander T, Xia Y, Raffelt D, Salvado O, Churilov L, Rowe CC, Brodtmann A, Villemagne VL, Connelly A. In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data. Neuroimage Clin 2020; 28:102479. [PMID: 33395971 PMCID: PMC7652769 DOI: 10.1016/j.nicl.2020.102479] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 09/25/2020] [Accepted: 10/19/2020] [Indexed: 12/13/2022]
Abstract
White matter hyperintensities (WMH) are regions of high signal intensity typically identified on fluid attenuated inversion recovery (FLAIR). Although commonly observed in elderly individuals, they are more prevalent in Alzheimer's disease (AD) patients. Given that WMH appear relatively homogeneous on FLAIR, they are commonly partitioned into location- or distance-based classes when investigating their relevance to disease. Since pathology indicates that such lesions are often heterogeneous, probing their microstructure in vivo may provide greater insight than relying on such arbitrary classification schemes. In this study, we investigated WMH in vivo using an advanced diffusion MRI method known as single-shell 3-tissue constrained spherical deconvolution (SS3T-CSD), which models white matter microstructure while accounting for grey matter and CSF compartments. Diffusion MRI data and FLAIR images were obtained from AD (n = 48) and healthy elderly control (n = 94) subjects. WMH were automatically segmented, and classified: (1) as either periventricular or deep; or (2) into three distance-based contours from the ventricles. The 3-tissue profile of WMH enabled their characterisation in terms of white matter-, grey matter-, and fluid-like characteristics of the diffusion signal. Our SS3T-CSD findings revealed substantial heterogeneity in the 3-tissue profile of WMH, both within lesions and across the various classes. Moreover, this heterogeneity information indicated that the use of different commonly used WMH classification schemes can result in different disease-based conclusions. We conclude that future studies of WMH in AD would benefit from inclusion of microstructural information when characterising lesions, which we demonstrate can be performed in vivo using SS3T-CSD.
Collapse
Affiliation(s)
- Remika Mito
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia; Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia.
| | - Thijs Dhollander
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia; Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia; Developmental Imaging, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
| | - Ying Xia
- CSIRO, Health & Biosecurity, The Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - David Raffelt
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia
| | - Olivier Salvado
- CSIRO, Health & Biosecurity, The Australian eHealth Research Centre, Brisbane, Queensland, Australia; CSIRO Data61, Sydney, New South Wales, Australia
| | - Leonid Churilov
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia; Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia
| | - Christopher C Rowe
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia; Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia; Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Amy Brodtmann
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia; Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia; Eastern Clinical Research Unit, Monash University, Box Hill Hospital, Melbourne, Victoria, Australia
| | - Victor L Villemagne
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia; Department of Medicine, Austin Health, University of Melbourne, Victoria, Australia; Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Alan Connelly
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia; Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
18
|
Fazlollahi A, Raniga P, Bourgeat P, Yates P, Bush AI, Salvado O, Ayton S. Restricted Effect of Cerebral Microbleeds on Regional Magnetic Susceptibility. J Alzheimers Dis 2020; 76:571-577. [DOI: 10.3233/jad-200076] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
| | | | | | - Paul Yates
- Department of Aged Care, Austin Health, Heidelberg, Victoria, Australia
| | - Ashley I. Bush
- University of Melbourne, Parkville, Victoria, Australia
- Melbourne Dementia Research Centre, Parkville, Victoria, Australia
- Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| | | | - Scott Ayton
- University of Melbourne, Parkville, Victoria, Australia
- Melbourne Dementia Research Centre, Parkville, Victoria, Australia
- Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
| |
Collapse
|
19
|
Burnham SC, Laws SM, Budgeon CA, Doré V, Porter T, Bourgeat P, Buckley RF, Murray K, Ellis KA, Turlach BA, Salvado O, Ames D, Martins RN, Rentz D, Masters CL, Rowe CC, Villemagne VL. Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition. Neurobiol Aging 2020; 95:46-55. [PMID: 32750666 DOI: 10.1016/j.neurobiolaging.2020.06.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Revised: 05/11/2020] [Accepted: 06/01/2020] [Indexed: 12/11/2022]
Abstract
Neocortical Aβ-amyloid deposition, one of the hallmark pathologic features of Alzheimer's disease (AD), begins decades prior to the presence of clinical symptoms. As clinical trials move to secondary and even primary prevention, understanding the rates of neocortical Aβ-amyloid deposition and the age at which Aβ-amyloid deposition becomes abnormal is crucial for optimizing the timing of these trials. As APOE-ε4 carriage is thought to modulate the age of clinical onset, it is also important to understand the impact of APOE-ε4 carriage on the age at which the neocortical Aβ-amyloid deposition becomes abnormal. Here, we show that, for 455 participants with over 3 years of follow-up, abnormal levels of neocortical Aβ-amyloid were reached on average at age 72 (66.5-77.1). The APOE-ε4 carriers reached abnormal levels earlier at age 63 (59.6-70.3); however, noncarriers reached the threshold later at age 78 (76.1-84.4). No differences in the rates of deposition were observed between APOE-ε4 carriers and noncarriers after abnormal Aβ-amyloid levels had been reached. These results suggest that primary and secondary prevention trials, looking to recruit at the earliest stages of disease, should target APOE-ε4 carriers between the ages of 60 and 66 and noncarriers between the ages of 76 and 84.
Collapse
Affiliation(s)
- Samantha C Burnham
- eHealth, CSIRO Health and Biosecurity, Parkville, Victoria, Australia; Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
| | - Simon M Laws
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia; Cooperative Research Centre for Mental Health, http://www.mentalhealthcrc.com, Perth, Western Australia, Australia
| | - Charley A Budgeon
- Centre for Applied Statistics, University of Western Australia, Crawley, Western Australia, Australia; eHealth, CSIRO Health and Biosecurity, Floreat, Western Australia, Australia
| | - Vincent Doré
- eHealth, CSIRO Health and Biosecurity, Herston, Queensland, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Tenielle Porter
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Cooperative Research Centre for Mental Health, http://www.mentalhealthcrc.com, Perth, Western Australia, Australia
| | - Pierrick Bourgeat
- eHealth, CSIRO Health and Biosecurity, Herston, Queensland, Australia
| | - Rachel F Buckley
- Florey Institute, University of Melbourne, Parkville, Victoria, Australia; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Victoria, Australia
| | - Kevin Murray
- School of Population and Global Health, University of Western Australia, Crawley, Western Australia, Australia
| | - Kathryn A Ellis
- Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Parkville, Victoria, Australia
| | - Berwin A Turlach
- Centre for Applied Statistics, University of Western Australia, Crawley, Western Australia, Australia
| | - Olivier Salvado
- eHealth, CSIRO Health and Biosecurity, Herston, Queensland, Australia; Florey Institute, University of Melbourne, Parkville, Victoria, Australia
| | - David Ames
- University of Melbourne Academic Unit for Psychiatry of Old Age, St George's Hospital, Kew, Victoria, Australia; National Ageing Research Institute, Parkville, Victoria, Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Dorene Rentz
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Colin L Masters
- Florey Institute, University of Melbourne, Parkville, Victoria, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia; Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia
| | - Victor L Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia; Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia
| | | | | |
Collapse
|
20
|
Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith SR, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P. Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults. Arch Clin Neuropsychol 2020; 34:585-598. [PMID: 30272115 DOI: 10.1093/arclin/acy078] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Revised: 08/20/2018] [Accepted: 09/11/2018] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE To prospectively examine 8-year risk of clinical disease progression to mild cognitive impairment (MCI)/dementia in older adults ≥60 with superior episodic memory (SuperAgers) compared to those cognitively normal for their age (CNFA). Additionally, to determine the extent to which SuperAgers were resilient to the negative effects of elevated amyloid-beta (Aβ+) on cognition. METHOD Participants were classified as SuperAgers based on episodic memory performance consistent with younger adults aged 30-44 and no impairment on non-memory tests (n = 179), and were matched with CNFA on age, sex, education, and follow-up time (n = 179). Subdistribution hazard models examined risk of clinical progression to MCI/dementia. Linear mixed models assessed the effect of Aβ on cognition over time. RESULTS Prevalence of Aβ+ and APOE ε4 was equivalent between SuperAgers and CNFA. SuperAgers had 69%-73% reduced risk of clinical progression to MCI/dementia compared to CNFA (HR: 0.27-0.31, 95% CI: 0.11-0.73, p < .001). Aβ+ was associated with cognitive decline in verbal memory and executive function, regardless of SuperAger/CNFA classification. In the absence of Aβ+, equivalent age-related changes in cognition were observed between SuperAgers and CNFA. CONCLUSIONS SuperAgers displayed resilience against clinical progression to MCI/dementia compared to CNFA despite equivalent risk for Alzheimer's disease (AD); however, SuperAgers had no greater protection from Aβ+ than CNFA. The deleterious effects of Aβ on cognition persist regardless of baseline cognitive ability. Thus, superior cognitive performance does not reflect resistance against the neuropathological processes associated with AD, and the observed resilience for SuperAgers may instead reflect neuropsychological criteria for cognitive impairment.
Collapse
Affiliation(s)
- Christa Dang
- Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia.,The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Karra D Harrington
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.,Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia
| | - Yen Ying Lim
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia.,National Ageing Research Institute, Parkville, Victoria, Australia
| | - Jason Hassenstab
- Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.,Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.,Department of Psychological & Brain Sciences, Washington University, St. Louis, MO, USA
| | - Simon M Laws
- Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia.,Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Western Australia, Australia
| | - Nawaf Yassi
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.,Department of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
| | - Martha Hickey
- Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia
| | - Stephanie R Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia
| | - Joanne Robertson
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Hamid R Sohrabi
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Department of Biomedical Sciences, Macquarie University, Sydney, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia.,School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia
| | - Victor L Villemagne
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.,Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Colin L Masters
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Paul Maruff
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.,CogState Ltd., Melbourne, Victoria, Australia
| | | |
Collapse
|
21
|
Armin MA, Barnes N, Grimpen F, Salvado O. Learning colon centreline from optical colonoscopy, a new way to generate a map of the internal colon surface. Healthc Technol Lett 2020; 6:187-190. [PMID: 32038855 PMCID: PMC6952246 DOI: 10.1049/htl.2019.0073] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Accepted: 10/02/2019] [Indexed: 11/20/2022] Open
Abstract
Optical colonoscopy is known as a gold standard screening method in detecting and removing cancerous polyps. During this procedure, some polyps may be undetected due to their positions, not being covered by the camera or missed by the surgeon. In this Letter, the authors introduce a novel convolutional neural network (ConvNet) algorithm to map the internal colon surface to a 2D map (visibility map), which can be used to increase the awareness of clinicians about areas they might miss. This was achieved by leveraging a colonoscopy simulator to generate a dataset consisting of colonoscopy video frames and their corresponding colon centreline (CCL) points in 3D camera coordinates. A pair of video frames were used as input to a ConvNet, whereas the output was a point on the CCL and its direction vector. By knowing CCL for each frame and roughly modelling the colon as a cylinder, frames could be unrolled to build a visibility map. They validated their results using both simulated and real colonoscopy frames. Their results showed that using consecutive simulated frames to learn the CCL can be generalised to real colonoscopy video frames to generate a visibility map.
Collapse
Affiliation(s)
| | - Nick Barnes
- CSIRO (Data61) 3D Computer Vision, Canberra, Australia.,College of Engineering and Computer Science (ANU), Canberra, Australia
| | - Florian Grimpen
- Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | | |
Collapse
|
22
|
Yassi N, Hilal S, Xia Y, Lim YY, Watson R, Kuijf H, Fowler C, Yates P, Maruff P, Martins R, Ames D, Chen C, Rowe CC, Villemagne VL, Salvado O, Desmond PM, Masters CL. Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer’s Disease. J Alzheimers Dis 2020; 73:897-907. [DOI: 10.3233/jad-191028] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Nawaf Yassi
- Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Parkville, Australia
- Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia
| | - Saima Hilal
- Memory Aging and Cognition Centre, Department of Pharmacology, National University of Singapore, Singapore
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore
| | - Ying Xia
- The Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation, Brisbane, Australia
| | - Yen Ying Lim
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia
| | - Rosie Watson
- Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia
- Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia
| | - Hugo Kuijf
- Image Sciences Institute, University Medical Center, Utrecht, Utrecht, Netherlands
| | - Christopher Fowler
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia
| | - Paul Yates
- Department of Aged Care Services, Austin Health, Heidelberg, Australia
- Department of Medicine, Austin Hospital, University of Melbourne, Heidelberg, Australia
| | | | - Ralph Martins
- Centre of Excellence for Alzheimer’s Disease Research and Care, Edith Cowan University, Perth, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, University of Melbourne, Parkville, Australia
- National Ageing Research Institute, Parkville, Australia
| | - Christopher Chen
- Memory Aging and Cognition Centre, Department of Pharmacology, National University of Singapore, Singapore
| | - Christopher C. Rowe
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia
- Florey Department of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia
| | - Victor L. Villemagne
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia
| | - Olivier Salvado
- Data61, Commonwealth Scientific and Industrial Research Organisation, Brisbane, Australia
| | - Patricia M. Desmond
- Department of Radiology, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia
| | - Colin L. Masters
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia
| |
Collapse
|
23
|
Shaw TB, Bollmann S, Atcheson NT, Strike LT, Guo C, McMahon KL, Fripp J, Wright MJ, Salvado O, Barth M. Non-linear realignment improves hippocampus subfield segmentation reliability. Neuroimage 2019; 203:116206. [DOI: 10.1016/j.neuroimage.2019.116206] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 09/14/2019] [Accepted: 09/17/2019] [Indexed: 01/08/2023] Open
|
24
|
Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith S, Robertson J, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P. Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. J Alzheimers Dis 2019; 65:1313-1325. [PMID: 30149452 DOI: 10.3233/jad-180507] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Preclinical Alzheimer's disease (AD) is defined by cerebral amyloid-β positivity (Aβ+) in cognitively normal (CN) older adults. OBJECTIVE To estimate the risk of progression to the symptomatic stages of AD due to PET Aβ+ and the extent that progression was influenced by other demographic, genetic, and clinical characteristics in a large prospective study. METHODS Fine-Gray subdistribution modeling was used to examine the risk of progression from CN to MCI/dementia due to Aβ+, APOEɛ4 carriage, and their interaction in the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging CN cohort (n = 599) over 8 years. RESULTS 17.7% Aβ+ and 8.1% Aβ-progressed over 8 years (OR: 2.43). Risk of progression for Aβ+ was 65-104% greater than Aβ-. Aβ+ APOEɛ4 carriers were at 348% greater risk than all other participants. Significant risk factors of progression in Aβ+ were age (HR: 1.05), PET SUVR (HR: 2.49) and APOE ɛ4 carriage (HR: 2.63); only age was a significant risk factor in Aβ-(HR: 1.09). Aβ-progressors were not near the threshold for Aβ+. These relationships were not moderated by hypertension, diabetes, obesity, or stroke/TIA. CONCLUSION Aβ+ is an important prognostic marker for progression from CN to MCI/dementia in older adults and APOEɛ4 carriage provides further predictive value in the presence of Aβ+. These data suggest that Aβ-associated clinical progression is consistent with clinical-pathological models of AD, whereas progression in the absence of elevated Aβ deposition may be the result of neuropathological processes other than AD that accumulate with age.
Collapse
Affiliation(s)
- Christa Dang
- Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, VIC, Australia.,The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Karra D Harrington
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Cooperative Research Centre for Mental Health, Parkville, VIC, Australia
| | - Yen Ying Lim
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - David Ames
- Department of Psychiatry, Academic Unit for Psychiatry of Old Age, The University of Melbourne, Parkville, VIC, Australia.,National Ageing Research Institute, Parkville, VIC, Australia
| | - Jason Hassenstab
- Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.,Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.,Department of Psychological and Brain Sciences, Washington University, St. Louis, MO, USA
| | - Simon M Laws
- Cooperative Research Centre for Mental Health, Parkville, VIC, Australia.,Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Western Australia, Australia
| | - Nawaf Yassi
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Department of Medicine and Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia
| | - Martha Hickey
- Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, VIC, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,Australian Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia
| | - Joanne Robertson
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Hamid R Sohrabi
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,School of Psychiatry and Clinical Neurosciences, University of WA, Nedlands, Western Australia, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, QLD, Australia
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,Australian Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia.,School of Psychological Science, University of Western Australia, Crawley, WA, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,CogState Ltd., Melbourne, VIC, Australia
| | | |
Collapse
|
25
|
Beaumont J, Saint-Jalmes H, Acosta O, Kober T, Tanner M, Ferré JC, Salvado O, Fripp J, Gambarota G. Multi T1-weighted contrast MRI with fluid and white matter suppression at 1.5 T. Magn Reson Imaging 2019; 63:217-225. [PMID: 31425812 DOI: 10.1016/j.mri.2019.08.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 08/11/2019] [Accepted: 08/15/2019] [Indexed: 11/16/2022]
Abstract
INTRODUCTION The fluid and white matter suppression sequence (FLAWS) provides two T1-weighted co-registered datasets: a white matter (WM) suppressed contrast (FLAWS1) and a cerebrospinal fluid (CSF) suppressed contrast (FLAWS2). FLAWS has the potential to improve the contrast of the subcortical brain regions that are important for Deep Brain Stimulation surgery planning. However, to date FLAWS has not been optimized for 1.5 T. In this study, the FLAWS sequence was optimized for use at 1.5 T. In addition, the contrast-enhancement properties of FLAWS image combinations were investigated using two voxel-wise FLAWS combined images: the division (FLAWS-div) and the high contrast (FLAWS-hc) image. METHODS FLAWS sequence parameters were optimized for 1.5 T imaging using an approach based on the use of a profit function under constraints for brain tissue signal and contrast maximization. MR experiments were performed on eleven healthy volunteers (age 18-30). Contrast (CN) and contrast to noise ratio (CNR) between brain tissues were measured in each volunteer. Furthermore, a qualitative assessment was performed to ensure that the separation between the internal globus pallidus (GPi) and the external globus pallidus (GPe) is identifiable in FLAWS1. RESULTS The optimized set of sequence parameters for FLAWS at 1.5 T provided contrasts similar to those obtained in a previous study at 3 T. The separation between the GPi and the GPe was clearly identified in FLAWS1. The CN of FLAWS-hc was higher than that of FLAWS1 and FLAWS2, but was not different from the CN of FLAWS-div. The CNR of FLAWS-hc was higher than that of FLAWS-div. CONCLUSION Both qualitative and quantitative assessments validated the optimization of the FLAWS sequence at 1.5 T. Quantitative assessments also showed that FLAWS-hc provides an enhanced contrast compared to FLAWS1 and FLAWS2, with a higher CNR than FLAWS-div.
Collapse
Affiliation(s)
- J Beaumont
- Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR1099, F-35000 Rennes, France; CSIRO, the Australian eHealth Research Centre, Herston, Queensland, Australia.
| | - H Saint-Jalmes
- Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR1099, F-35000 Rennes, France
| | - O Acosta
- Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR1099, F-35000 Rennes, France
| | - T Kober
- Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, Switzerland; Department of Radiology, University Hospital (CHUV), Lausanne, Switzerland; LTS5, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - M Tanner
- Invicro, A Konica Minolta Company, London, UK
| | - J C Ferré
- Univ Rennes, Inria, CNRS, INSERM, IRISA, VISAGES ERL U-1228, F-35000 Rennes, France; CHU Rennes, Department of Neuroradiology, F-35033 Rennes, France
| | - O Salvado
- CSIRO, Data61, Herston, Queensland, Australia
| | - J Fripp
- CSIRO, the Australian eHealth Research Centre, Herston, Queensland, Australia
| | - G Gambarota
- Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR1099, F-35000 Rennes, France
| |
Collapse
|
26
|
Dang C, Yassi N, Harrington KD, Xia Y, Lim YY, Ames D, Laws SM, Hickey M, Rainey-Smith S, Sohrabi HR, Doecke JD, Fripp J, Salvado O, Snyder PJ, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P. Rates of age- and amyloid β-associated cortical atrophy in older adults with superior memory performance. Alzheimers Dement (Amst) 2019; 11:566-575. [PMID: 31909172 PMCID: PMC6939054 DOI: 10.1016/j.dadm.2019.05.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Introduction Superior cognitive performance in older adults may reflect underlying resistance to age-associated neurodegeneration. While elevated amyloid β (Aβ) deposition (Aβ+) has been associated with increased cortical atrophy, it remains unknown whether “SuperAgers” may be protected from Aβ-associated neurodegeneration. Methods Neuropsychologically defined SuperAgers (n = 172) and cognitively normal for age (n = 172) older adults from the Australian Imaging, Biomarkers and Lifestyle study were case matched. Rates of cortical atrophy over 8 years were examined by SuperAger classification and Aβ status. Results Of the case-matched SuperAgers and cognitively normal for age older adults, 40.7% and 40.1%, respectively, were Aβ+. Rates of age- and Aβ-associated atrophy did not differ between the groups on any measure. Aβ− individuals displayed the slowest rates of atrophy. Discussion Maintenance of superior memory in late life does not reflect resistance to age- or Aβ-associated atrophy. However, those individuals who reached old age without cognitive impairment nor elevated Aβ deposition (i.e. Aβ−) displayed reduced rates of cortical atrophy.
Collapse
Affiliation(s)
- Christa Dang
- Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia.,The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Nawaf Yassi
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.,Department of Medicine and Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Karra D Harrington
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.,Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia
| | - Ying Xia
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Yen Ying Lim
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia.,National Ageing Research Institute, Parkville, Victoria, Australia
| | - Simon M Laws
- Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia.,Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia
| | - Martha Hickey
- Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,Australian Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia
| | - Hamid R Sohrabi
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,School of Psychiatry and Clinical Neurosciences, University of Western Australia, Nedlands, Western Australia, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Peter J Snyder
- George & Anne Ryan Institute for Neuroscience, The University of Rhode Island, Kingston, RI, USA
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,Australian Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia.,School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.,Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.,CogState Ltd., Melbourne, Victoria, Australia
| | | |
Collapse
|
27
|
McCombe PA, Ngo ST, Guo CC, Fazlollahi A, Bollmann S, Wang L, Hu X, Barth M, Salvado O, Davis M, Ceslis A, Robinson G, Henderson RD, Steyn FJ. Patient with ALS with a novel TBK1 mutation, widespread brain involvement, behaviour changes and metabolic dysfunction. J Neurol Neurosurg Psychiatry 2019; 90:952-954. [PMID: 30196251 PMCID: PMC6691862 DOI: 10.1136/jnnp-2018-318823] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 08/13/2018] [Accepted: 08/20/2019] [Indexed: 12/12/2022]
Affiliation(s)
- Pamela A McCombe
- Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.,Wesley Medical Research, The Wesley Hospital, Brisbane, Auchenflower, Australia.,Department of Neurology, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia.,School of Medicine, The University of Queensland, Brisbane, Queensland, Australia
| | - Shyuan T Ngo
- Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.,Wesley Medical Research, The Wesley Hospital, Brisbane, Auchenflower, Australia.,Department of Neurology, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia.,Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia.,Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia
| | - Christine Cong Guo
- QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.,School of Automation, Northwestern Polytechnical University, Xi'an, China
| | - Amir Fazlollahi
- The Australian E-Health Research Centre, CSIRO Health and Biosecurity, Sydney, Queensland, Australia
| | - Saskia Bollmann
- Centre for Advanced Imaging, The University of Queensland, Brisbane, Queensland, Australia
| | - Liting Wang
- School of Automation, Northwestern Polytechnical University, Xi'an, China
| | - Xintao Hu
- School of Automation, Northwestern Polytechnical University, Xi'an, China
| | - Markus Barth
- Centre for Advanced Imaging, The University of Queensland, Brisbane, Queensland, Australia
| | - Olivier Salvado
- The Australian E-Health Research Centre, CSIRO Health and Biosecurity, Sydney, Queensland, Australia.,CSIRO Data61, Australian Technology Park, Brisbane, Queensland, Australia
| | - Mark Davis
- Neurogenetics Unit, Department of Diagnostic Genomics, Path West Laboratory Medicine, Brisbane, Queensland, Australia
| | - Amelia Ceslis
- Department of Neurology, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia.,Neuropsychology Research Unit, School of Psychology, The University of Queensland, Brisbane, Queensland, Australia
| | - Gail Robinson
- Department of Neurology, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia.,Neuropsychology Research Unit, School of Psychology, The University of Queensland, Brisbane, Queensland, Australia
| | - Robert D Henderson
- Wesley Medical Research, The Wesley Hospital, Brisbane, Auchenflower, Australia.,Department of Neurology, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia.,School of Medicine, The University of Queensland, Brisbane, Queensland, Australia.,Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia
| | - Frederik J Steyn
- Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia .,Wesley Medical Research, The Wesley Hospital, Brisbane, Auchenflower, Australia.,Department of Neurology, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia.,Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia
| |
Collapse
|
28
|
Mito R, Raffelt D, Dhollander T, Vaughan DN, Tournier JD, Salvado O, Brodtmann A, Rowe CC, Villemagne VL, Connelly A. Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease? Brain 2019; 141:e45. [PMID: 29668851 DOI: 10.1093/brain/awy086] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Affiliation(s)
- Remika Mito
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, 3084, Australia.,Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, 3084, Australia
| | - David Raffelt
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, 3084, Australia
| | - Thijs Dhollander
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, 3084, Australia
| | - David N Vaughan
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, 3084, Australia.,Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, 3084, Australia.,Department of Neurology, Austin Health, Heidelberg, Victoria, 2084, Australia
| | - J-Donald Tournier
- Department of Biomedical Engineering, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, WC2R 2LS, UK.,Centre for the Developing Brain, King's College London, London, WC2R 2LS, UK
| | - Olivier Salvado
- CSIRO, Health and Biosecurity, The Australian eHealth Research Centre, Brisbane, Queensland, 4029, Australia
| | - Amy Brodtmann
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, 3084, Australia.,Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, 3084, Australia.,Eastern Clinical Research Unit, Monash University, Box Hill Hospital, Melbourne, Victoria, 3128, Australia
| | - Christopher C Rowe
- Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, 3084, Australia.,Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, 3084, Australia
| | - Victor L Villemagne
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, 3084, Australia.,Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, 3084, Australia.,Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, 3084, Australia
| | - Alan Connelly
- Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, 3084, Australia.,Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, 3084, Australia
| |
Collapse
|
29
|
Fazlollahi A, Calamante F, Liang X, Bourgeat P, Raniga P, Dore V, Fripp J, Ames D, Masters CL, Rowe CC, Connelly A, Villemagne VL, Salvado O. Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease. J Magn Reson Imaging 2019; 51:505-513. [PMID: 31145515 DOI: 10.1002/jmri.26810] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Accepted: 05/15/2019] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Arterial spin labeling (ASL) is an emerging MRI technique for noninvasive measurement of cerebral blood flow (CBF) that has been used to show hemodynamic changes in the brains of people with Alzheimer's disease (AD). CBF changes have been measured using positron emission tomography (PET) across the AD spectrum, but ASL showed limited success in measuring CBF variations in the preclinical phase of AD, where amyloid β (Aβ) plaques accumulate in the decades prior to symptom onset. PURPOSE To investigate the relationship between CBF measured by multiphase-pseudocontinuous-ASL (MP-PCASL) and Aβ burden as measured by 11 C-PiB PET imaging in a study of cognitively normal (CN) subjects age over 65. STUDY TYPE Cross-sectional. POPULATION Forty-six CN subjects including 33 with low levels of Aβ burden and 13 with high levels of Aβ. FIELD STRENGTH/SEQUENCE 3T/3D MP-PCASL. ASSESSMENT The MP-PCASL method was chosen because it has a high signal-to-noise ratio. Furthermore, the data were analyzed using an efficient processing pipeline consisting of motion correction, ASL motion correction imprecision removal, temporal and spatial filtering, and partial volume effect correction. STATISTICAL TESTS General Linear Model. RESULTS In CN subjects positive for Aβ burden (n = 13), we observed a positive correlation between CBF and Aβ burden in the hippocampus, amygdala, caudate (P < 0.01), frontal, temporal, and insula (P < 0.05). DATA CONCLUSION To the best of our knowledge, this is the first study using MP-PCASL in the study of AD, and the results suggest a potential compensatory hemodynamic mechanism that protects against pathology in the early stages of AD. LEVEL OF EVIDENCE 1 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2020;51:505-513.
Collapse
Affiliation(s)
| | - Fernando Calamante
- University of Sydney, Sydney Imaging and School of Aerospace, Mechanical and Mechatronic Engineering, Sydney, Australia.,Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia.,Florey Department of Neuroscience & Mental Health, University of Melbourne, Australia
| | - Xiaoyun Liang
- Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia.,Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia
| | | | | | - Vincent Dore
- CSIRO Health and Biosecurity, Brisbane, Australia.,Austin Health, Heidelberg, Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Brisbane, Australia
| | - David Ames
- University of Melbourne, Parkville, Australia
| | - Colin L Masters
- Florey Department of Neuroscience & Mental Health, University of Melbourne, Australia.,University of Melbourne, Parkville, Australia
| | - Christopher C Rowe
- Austin Health, Heidelberg, Australia.,University of Melbourne, Parkville, Australia
| | - Alan Connelly
- Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia.,Florey Department of Neuroscience & Mental Health, University of Melbourne, Australia
| | - Victor L Villemagne
- Austin Health, Heidelberg, Australia.,University of Melbourne, Parkville, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity, Brisbane, Australia.,CSIRO Data61, Sydney, Australia
| | | |
Collapse
|
30
|
Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens AW, Barthel H, Fripp J, Masters CL, Dinkelborg L, Salvado O, Villemagne VL, De Santi S. Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL ® approaches: Validation against histopathology. Alzheimers Dement 2019; 15:807-816. [PMID: 31101517 DOI: 10.1016/j.jalz.2019.02.005] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 02/15/2019] [Accepted: 02/25/2019] [Indexed: 01/22/2023]
Abstract
INTRODUCTION 18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. METHODS Data from eighty-eight subjects (52 male subjects, aged 79.8 ± 10.6 years) who underwent antemortem 18F-florbetaben positron emission tomography scan and magnetic resonance imaging less than a year before neuropathological assessment at autopsy were evaluated. Image analysis was performed using the standard Centiloid (CL) statistical parametric mapping approach and CapAIBL®. Imaging results were compared against autopsy data. RESULTS Against combined Bielschowsky silver staining and immunohistochemistry histopathological scores, statistical parametric mapping had 96% sensitivity, 96% specificity, and 95% accuracy, whereas magnetic resonance-less CapAIBL standardized uptake value ratioWhole Cerebellum had 94% sensitivity, 96% specificity, and 95% accuracy. Based on the combined histopathological scores, a CL threshold band of 19 ± 7 CL was determined. DISCUSSION Quantification of 18F-florbetaben positron emission tomography scans using magnetic resonance-based and magnetic resonance-less CapAIBL® approaches showed high agreement, establishing a pathology-based threshold in CL.
Collapse
Affiliation(s)
- Vincent Doré
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia.
| | | | - Christopher C Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia
| | - Salamata Konate
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia
| | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | | | - Henryk Barthel
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Jurgen Fripp
- CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia
| | - Colin L Masters
- The Florey Institute of Neurosciences and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | | | - Olivier Salvado
- CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia
| | - Victor L Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia
| | | |
Collapse
|
31
|
Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Sohrabi HR, Peretti M, Lim YY, Weinborn M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM. COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults. IBRO Rep 2019; 6:147-152. [PMID: 31080907 PMCID: PMC6506436 DOI: 10.1016/j.ibror.2019.05.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 05/01/2019] [Indexed: 11/26/2022] Open
Abstract
The non-synonymous single nucleotide polymorphism (SNP), Val158Met within the Catechol-O-methyltransferase (COMT) gene has been associated with altered levels of cognition and memory performance in cognitively normal adults. This study aimed to investigate the independent and interactional effects of COMT Val158Met on cognitive performance. In particular, it was hypothesised that COMT Val158Met would modify the effect of neocortical Aβ-amyloid (Aβ) accumulation and carriage of the apolipoprotein E (APOE) ε4 allele on cognition in preclinical Alzheimer's disease (AD). In 598 cognitively normal older adults with known neocortical Aβ levels, linear mixed modelling revealed no significant independent or interactional associations between COMT Val158Met and cognitive decline. These findings do not support previous associations between COMT Val158Met and cognitive performance and suggest this variant does not influence Aβ-amyloid or APOE ε4 driven cognitive decline in a well characterised cohort of cognitively normal older adults.
Collapse
Affiliation(s)
- Tenielle Porter
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia.,Cooperative Research Centre for Mental Health, Australia
| | - Samantha C Burnham
- CSIRO Health and Biosecurity, Parkville 3052, Victoria, Australia.,Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia
| | - Lidija Milicic
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia.,Cooperative Research Centre for Mental Health, Australia
| | - Greg Savage
- ARC Centre of Excellence in Cognition and its Disorders, Department of Psychology, Macquarie University, North Ryde 2113, NSW, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3052, Victoria, Australia.,CogState Ltd., Melbourne 3000, Victoria, Australia
| | - Hamid R Sohrabi
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia
| | - Madeline Peretti
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia.,Cooperative Research Centre for Mental Health, Australia
| | - Yen Ying Lim
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3052, Victoria, Australia
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia.,School of Psychology, University of Western Australia, Crawley 6009, Western Australia, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew 3101, Victoria, Australia.,National Ageing Research Institute, Parkville 3052, Victoria, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3052, Victoria, Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia
| | - Christopher C Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg 3084, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Heidelberg 3084, Victoria, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity/Australian e-Health Research Centre, Herston 4029, Queensland, Australia
| | - David Groth
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Western Australia, Australia
| | - Giuseppe Verdile
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Western Australia, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3052, Victoria, Australia.,Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg 3084, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Heidelberg 3084, Victoria, Australia
| | - Simon M Laws
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia.,Cooperative Research Centre for Mental Health, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Western Australia, Australia
| |
Collapse
|
32
|
Bransby L, Lim YY, Ames D, Fowler C, Roberston J, Harrington K, Snyder PJ, Villemagne VL, Salvado O, Masters CL, Maruff P. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease. J Clin Exp Neuropsychol 2019; 41:591-600. [PMID: 30924399 DOI: 10.1080/13803395.2019.1593949] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Introduction: Preclinical Alzheimer's disease (AD) is characterized by amyloid-related cognitive decline. Reduction in this decline is used to determine the efficacy of drug therapies designed to forestall the disease in preclinical AD clinical trials, measured by a Preclinical Alzheimer's Cognitive Composite (PACC). Most studies estimate rates of cognitive change by comparing cognitively normal (CN) older adults with abnormally high beta-amyloid (Aβ+) to those with low levels (Aβ-). However, participants of preclinical AD clinical trials must be Aβ+ for entry. Therefore, we estimated the effect of very high amyloid (Aβ++) and Aβ+ on cognitive change over three years measured by different versions of the PACC in individuals with preclinical AD. Method: CN older adults underwent Aβ neuroimaging and neuropsychological assessments over three years as part of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Three cognitive composite scores were computed: the Alzheimer's Disease Cooperative Study (ADCS)-PACC, the ADCS-PACC with no Mini-Mental State Examination (MMSE), and the z-scores of Attention, Verbal Fluency and Episodic Memory for Nondemented Older Adults (ZAVEN) composite. Results: Compared to the Aβ++ group, the Aβ+ group showed a slower rate of cognitive decline with the largest magnitude of difference reflected by the ADCS-PACC (d = 0.85). The ADCS-PACC excluding the MMSE and the ZAVEN also reflected a moderate to large magnitude of difference between groups (d = 0.62, d = 0.72, respectively). Conclusions: When all individuals have abnormal Aβ, the level of Aβ at baseline is associated with the rate of subsequent decline. The ADCS-PACC was the most sensitive composite score in showing that lower Aβ is associated with a slower rate of cognitive decline; however, there are limitations to the use of the MMSE. These results provide a benchmark of comparison for preclinical AD clinical trials aiming to slow cognitive deterioration.
Collapse
Affiliation(s)
- Lisa Bransby
- a The Florey Institute of Neuroscience and Mental Health , The University of Melbourne , Melbourne , VIC , Australia
| | - Yen Ying Lim
- a The Florey Institute of Neuroscience and Mental Health , The University of Melbourne , Melbourne , VIC , Australia
| | - David Ames
- b National Ageing Research Institute , Melbourne , VIC , Australia.,c Academic Unit for Psychiatry of Old Age, St. Vincent's Health , The University of Melbourne , Melbourne , VIC , Australia
| | - Christopher Fowler
- a The Florey Institute of Neuroscience and Mental Health , The University of Melbourne , Melbourne , VIC , Australia
| | - Joanne Roberston
- a The Florey Institute of Neuroscience and Mental Health , The University of Melbourne , Melbourne , VIC , Australia
| | - Karra Harrington
- a The Florey Institute of Neuroscience and Mental Health , The University of Melbourne , Melbourne , VIC , Australia.,d Cooperative Research Centre for Mental Health , Parkville , Australia
| | - Peter J Snyder
- e Ryan Institute for Neuroscience , University of Rhode Island , Kingston , RI , USA
| | - Victor L Villemagne
- a The Florey Institute of Neuroscience and Mental Health , The University of Melbourne , Melbourne , VIC , Australia.,f Department of Nuclear Medicine and Centre for PET , Austin Health , Melbourne , VIC , Australia.,g Department of Medicine, Austin Health , The University of Melbourne , Melbourne , VIC , Australia
| | - Olivier Salvado
- h Commonwealth Scientific Industrial Research Organization (CSIRO) Preventative Health National Research Flagship , Australian e-Health Research Centre-BiaMedIA , Brisbane , QLD , Australia
| | - Colin L Masters
- a The Florey Institute of Neuroscience and Mental Health , The University of Melbourne , Melbourne , VIC , Australia
| | - Paul Maruff
- a The Florey Institute of Neuroscience and Mental Health , The University of Melbourne , Melbourne , VIC , Australia.,i CogState Ltd ., Melbourne , VIC , Australia
| |
Collapse
|
33
|
Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM. Klotho allele status is not associated with Aβ and APOE ε4-related cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging 2019; 76:162-165. [PMID: 30716541 DOI: 10.1016/j.neurobiolaging.2018.12.014] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 12/04/2018] [Accepted: 12/27/2018] [Indexed: 11/30/2022]
Abstract
The longevity gene Klotho (KL), specifically the functional KL-VS variant, has previously been associated with cognition and rates of cognitive decline. This study aimed to determine whether KL-VS associations with cognition were observable in preclinical Alzheimer's disease (AD). The study also aimed to determine whether there was a combined influence of KL-VS, neocortical amyloid-β (Aβ) burden, and carriage of the apolipoprotein E (APOE) ε4 allele on cognitive decline. This study involved 581 Aβ-imaged, cognitively normal older adults, enrolled in the Australian Imaging, Biomarkers and Lifestyle Study of Aging. Linear mixed effects models revealed no significant associations between KL-VS and cognitive decline independently or in combination with Aβ burden and APOE ε4 genotype. Overall, previous associations reported between KL-VS and cognitive decline are not observed at the preclinical stages of AD. Furthermore, the results do not support the hypothesis that KL-VS has a modifying effect on Aβ burden and APOE ε4-driven cognitive decline in preclinical AD.
Collapse
Affiliation(s)
- Tenielle Porter
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Cooperative Research Centre for Mental Health, Carlton South, Victoria, Australia
| | - Samantha C Burnham
- CSIRO Health and Biosecurity, Parkville, Victoria, Australia; Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Lidija Milicic
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Cooperative Research Centre for Mental Health, Carlton South, Victoria, Australia
| | - Greg Savage
- Department of Psychology, ARC Centre of Excellence in Cognition and its Disorders, Macquarie University, North Ryde, NSW, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; CogState Ltd., Melbourne, Victoria, Australia
| | - Yen Ying Lim
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, Victoria, Australia; National Ageing Research Institute, Parkville, Victoria, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Christopher C Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia; Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity/Australian e-Health Research Centre, Herston, Queensland, Australia
| | - David Groth
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | - Giuseppe Verdile
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia; Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
| | - Simon M Laws
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Cooperative Research Centre for Mental Health, Carlton South, Victoria, Australia; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.
| |
Collapse
|
34
|
Porter T, Burnham SC, Savage G, Lim YY, Maruff P, Milicic L, Peretti M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Taddei K, Groth D, Verdile G, Villemagne VL, Laws SM. A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. Front Aging Neurosci 2018; 10:423. [PMID: 30620773 PMCID: PMC6305908 DOI: 10.3389/fnagi.2018.00423] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Accepted: 12/06/2018] [Indexed: 01/29/2023] Open
Abstract
Studies of Alzheimer’s disease risk-weighted polygenic risk scores (PRSs) for cognitive performance have reported inconsistent associations. This inconsistency is particularly evident when PRSs are assessed independent of APOE genotype. As such, the development and assessment of phenotype-specific weightings to derive PRSs for cognitive decline in preclinical AD is warranted. To this end a episodic memory-weighted PRS (emPRS) was derived and assessed against decline in cognitive performance in 226 healthy cognitively normal older adults with high brain Aβ-amyloid burden participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. The effect size for decline in a verbal episodic memory was determined individually for 27 genetic variants in a reference sample (n = 151). These were then summed to generate a emPRS either including APOE (emPRSc¯APOE) or excluding APOE (emPRSs¯APOE). Resultant emPRS were then evaluated, in a test sample (n = 75), against decline in global cognition, verbal episodic memory and a pre-Alzheimer’s cognitive composite (AIBL-PACC) over 7.5 years. The mean (SD) age of the 226 participants was 72.2 (6.6) years and 116 (51.3%) were female. Reference and test samples did not differ significantly demographically. Whilst no association of emPRSs were observed with baseline cognition, the emPRSc¯APOE was associated with longitudinal global cognition (-0.237, P = 0.0002), verbal episodic memory (-0.259, P = 0.00003) and the AIBL-PACC (-0.381, P = 0.02). The emPRSs¯APOE was also associated with global cognition (-0.169, P = 0.021) and verbal episodic memory (-0.208, P = 0.004). Stratification by APOE ε4 revealed that the association between the emPRS and verbal episodic memory was limited to carriage of no ε4 or one ε4 allele. This was also observed for global cognition. The emPRS and rates of decline in AIBL-PACC were associated in those carrying one ε4 allele. Overall, the described novel emPRS has utility for the prediction of decline in cognition in preclinical AD. This study provides evidence to support the further use and evaluation of phenotype weightings in PRS development.
Collapse
Affiliation(s)
- Tenielle Porter
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Cooperative Research Centre (CRC) for Mental Health, Carlton, VIC, Australia
| | - Samantha C Burnham
- CSIRO Health and Biosecurity, Parkville, VIC, Australia.,Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Greg Savage
- ARC Centre of Excellence in Cognition and its Disorders, Department of Psychology, Macquarie University, North Ryde, NSW, Australia
| | - Yen Ying Lim
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,CogState Ltd., Melbourne, VIC, Australia
| | - Lidija Milicic
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Cooperative Research Centre (CRC) for Mental Health, Carlton, VIC, Australia
| | - Madeline Peretti
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Cooperative Research Centre (CRC) for Mental Health, Carlton, VIC, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, VIC, Australia.,National Ageing Research Institute, Parkville, VIC, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Christopher C Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia
| | | | - Kevin Taddei
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - David Groth
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| | - Giuseppe Verdile
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia
| | - Simon M Laws
- Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Cooperative Research Centre (CRC) for Mental Health, Carlton, VIC, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| |
Collapse
|
35
|
Bourgeat P, Doré V, Fripp J, Ames D, Masters CL, Salvado O, Villemagne VL, Rowe CC. Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL. Neuroimage 2018; 183:387-393. [DOI: 10.1016/j.neuroimage.2018.08.044] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 07/09/2018] [Accepted: 08/17/2018] [Indexed: 10/28/2022] Open
|
36
|
Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Li QX, Ames D, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM. Utility of an Alzheimer’s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer’s Disease: A Prospective Longitudinal Study. J Alzheimers Dis 2018; 66:1193-1211. [DOI: 10.3233/jad-180713] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Tenielle Porter
- Collaborative Genomics Group, Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Co-operative Research Centre for Mental Health,
| | - Samantha C. Burnham
- eHealth, CSIRO Health and Biosecurity, Parkville, VIC, Australia
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Lidija Milicic
- Collaborative Genomics Group, Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Co-operative Research Centre for Mental Health,
| | - Greg Savage
- Department of Psychology, ARC Centre of Excellence in Cognition and its Disorders, Macquarie University, NSW, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- CogState Ltd., Melbourne, VIC, Australia
| | - Yen Ying Lim
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Qiao-Xin Li
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, St. Vincent’s Health, The University of Melbourne, Kew, VIC, Australia
- National Ageing Research Institute, Parkville, VIC, Australia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Christopher C. Rowe
- Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, VIC, Australia
- Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia
| | - Olivier Salvado
- Collaborative Genomics Group, Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - David Groth
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | - Giuseppe Verdile
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | - Victor L. Villemagne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, VIC, Australia
- Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia
| | - Simon M. Laws
- Collaborative Genomics Group, Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Co-operative Research Centre for Mental Health,
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia
| | | |
Collapse
|
37
|
Manjón JV, Coupé P, Raniga P, Xia Y, Desmond P, Fripp J, Salvado O. MRI white matter lesion segmentation using an ensemble of neural networks and overcomplete patch-based voting. Comput Med Imaging Graph 2018; 69:43-51. [DOI: 10.1016/j.compmedimag.2018.05.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Revised: 04/21/2018] [Accepted: 05/01/2018] [Indexed: 12/11/2022]
|
38
|
Chandra SS, Dowling JA, Engstrom C, Xia Y, Paproki A, Neubert A, Rivest-Hénault D, Salvado O, Crozier S, Fripp J. A lightweight rapid application development framework for biomedical image analysis. Comput Methods Programs Biomed 2018; 164:193-205. [PMID: 30195427 DOI: 10.1016/j.cmpb.2018.07.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 07/11/2018] [Accepted: 07/24/2018] [Indexed: 06/08/2023]
Abstract
Biomedical imaging analysis typically comprises a variety of complex tasks requiring sophisticated algorithms and visualising high dimensional data. The successful integration and deployment of the enabling software to clinical (research) partners, for rigorous evaluation and testing, is a crucial step to facilitate adoption of research innovations within medical settings. In this paper, we introduce the Simple Medical Imaging Library Interface (SMILI), an object oriented open-source framework with a compact suite of objects geared for rapid biomedical imaging (cross-platform) application development and deployment. SMILI supports the development of both command-line (shell and Python scripting) and graphical applications utilising the same set of processing algorithms. It provides a substantial subset of features when compared to more complex packages, yet it is small enough to ship with clinical applications with limited overhead and has a license suitable for commercial use. After describing where SMILI fits within the existing biomedical imaging software ecosystem, by comparing it to other state-of-the-art offerings, we demonstrate its capabilities in creating a clinical application for manual measurement of cam-type lesions of the femoral head-neck region for the investigation of femoro-acetabular impingement (FAI) from three dimensional (3D) magnetic resonance (MR) images of the hip. This application for the investigation of FAI proved to be convenient for radiological analyses and resulted in high intra (ICC=0.97) and inter-observer (ICC=0.95) reliabilities for measurement of α-angles of the femoral head-neck region. We believe that SMILI is particularly well suited for prototyping biomedical imaging applications requiring user interaction and/or visualisation of 3D mesh, scalar, vector or tensor data.
Collapse
Affiliation(s)
- Shekhar S Chandra
- School of Information Technology and Electrical Engineering, The University of Queensland, Australia.
| | | | - Craig Engstrom
- School of Human Movement Studies, The University of Queensland, Australia
| | - Ying Xia
- Australian e-Health Research Centre, CSIRO, Australia
| | - Anthony Paproki
- Australian e-Health Research Centre, CSIRO, Australia; School of Information Technology and Electrical Engineering, The University of Queensland, Australia
| | - Aleš Neubert
- Australian e-Health Research Centre, CSIRO, Australia
| | | | | | - Stuart Crozier
- School of Information Technology and Electrical Engineering, The University of Queensland, Australia
| | - Jurgen Fripp
- Australian e-Health Research Centre, CSIRO, Australia
| |
Collapse
|
39
|
Cummins TL, Xia Y, Elias A, Lamb F, Pannek K, Dore V, Bourgeat P, Williams R, Salvado O, Fripp J, Ponsford J, Villemagne VL, Hopwood M, Rowe C. O4‐07‐02: TAU, Aβ‐AMYLOID, BRAIN STRUCTURE AND COGNITIVE FUNCTION FOLLOWING SERVICE‐RELATED TRAUMATIC BRAIN INJURY IN AUSTRALIAN VIETNAM WAR VETERANS. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Tia L. Cummins
- Austin HealthMelbourneAustralia
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Ying Xia
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | | | | | - Kerstin Pannek
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Vincent Dore
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Pierrick Bourgeat
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Robert Williams
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Olivier Salvado
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Jurgen Fripp
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | | | | | | | - Christopher Rowe
- Austin HealthMelbourneAustralia
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| |
Collapse
|
40
|
Villemagne VL, Dore V, Okamura N, Baxendale D, Harada R, Mulligan RS, Furumoto S, Salvado O, Yanai K, Masters CL, Rowe CC. IC‐P‐223: TO TAU OR TO MAO‐B? MOST OF THE [F‐18]‐THK5351 SIGNAL IS BLOCKED BY SELEGILINE. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Victor L. Villemagne
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
- Austin HealthMelbourneAustralia
| | | | | | | | - Ryuichi Harada
- Tohoku UniversityGraduate School of MedicineSendai CityJapan
| | | | | | | | | | - Colin L. Masters
- Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | | |
Collapse
|
41
|
Cummins TL, Xia Y, Elias A, Lamb F, Pannek K, Dore V, Bourgeat P, Williams R, Salvado O, Fripp J, Ponsford J, Villemagne VL, Hopwood M, Rowe C. IC‐P‐091: TAU, Aβ‐AMYLOID, BRAIN STRUCTURE AND COGNITIVE FUNCTION FOLLOWING SERVICE‐RELATED TRAUMATIC BRAIN INJURY IN AUSTRALIAN VIETNAM WAR VETERANS. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Tia L. Cummins
- Austin HealthMelbourneAustralia
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Ying Xia
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | | | | | - Kerstin Pannek
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Vincent Dore
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Pierrick Bourgeat
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Robert Williams
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Olivier Salvado
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Jurgen Fripp
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | | | | | | | - Christopher Rowe
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| |
Collapse
|
42
|
Dore V, Bourgeat P, Cummins TL, Raniga P, Williams S, Amadoru S, MacLean C, Hinton F, Shepherd C, Halliday GM, Leyton CE, Hodges JR, Ames D, Martins RN, Masters CL, Fripp J, Salvado O, Villemagne VL, Rowe C. P1‐405: VISUAL ASSESSMENT OF β‐AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Vincent Dore
- CSIROBrisbaneAustralia
- Austin HealthMelbourneAustralia
| | | | - Tia L. Cummins
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | | | | | | | | | - Fairlie Hinton
- The Florey Institute of Neuroscience and Mental HealthParkvilleAustralia
| | | | - Glenda M. Halliday
- Neuroscience Research AustraliaUniversity of New South WalesSydneyAustralia
| | | | - John R. Hodges
- ARC Centre of Excellence in Cognition and its DisordersSydneyAustralia
| | - David Ames
- The University of MelbourneParkvilleAustralia
| | | | - Colin L. Masters
- Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | | | | | | | - Christopher Rowe
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| |
Collapse
|
43
|
Williams S, Bourgeat P, Villemagne VL, Fripp J, Salvado O, Rowe CC, Dore V. P2‐385: PARTIAL VOLUME CORRECTION USING EITHER PMOD
®
OR CAPAIBL
®
DOES LITTLE TO IMPROVE
18
F‐AV1451 PET QUANTIFICATION. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Burnham SC, Bourgeat P, Budgeon CA, Dore V, Savage G, Laws SM, Salvado O, Maruff P, Martins RN, Ames D, Sperling RA, Masters CL, Rowe CC, Villemagne VL. O4‐09‐01: COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL Aβ‐AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Samantha C. Burnham
- Commonwealth Scientific and Industrial Research OrganisationMelbourneAustralia
| | - Pierrick Bourgeat
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Charley Ann Budgeon
- Commonwealth Scientific and Industrial Research OrganisationPerthAustralia
- University of Western AustraliaPerthAustralia
| | - Vincent Dore
- Commonwealth Scientific and Industrial Research OrganisationBrisaneAustralia
| | | | - Simon M. Laws
- Edith Cowan UniversityJoondalupAustralia
- Curtin UniversityPerthAustralia
| | - Olivier Salvado
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
- Cogstate Ltd.MelbourneAustralia
| | - Ralph N. Martins
- Edith Cowan UniversityJoondalupAustralia
- University of Western AustraliaPerthAustralia
- Macquarie UniversityNorth RydeAustralia
| | - David Ames
- University of MelbourneParkvilleAustralia
- National Ageing Research InstituteMelbourneAustralia
| | - Reisa A. Sperling
- Brigham and Women's HospitalHarvard Medical SchoolBostonMAUSA
- Massachusetts General HospitalBostonMAUSA
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
- University of MelbourneParkvilleAustralia
| | | | - Victor L. Villemagne
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
- Austin HealthMelbourneAustralia
| |
Collapse
|
45
|
Williams S, Bourgeat P, Villemagne VL, Fripp J, Salvado O, Rowe CC, Dore V. IC‐P‐225: PARTIAL VOLUME CORRECTION USING EITHER PMOD
®
OR CAPAIBL
®
DOES LITTLE TO IMPROVE
18
F‐AV1451 PET QUANTIFICATION. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | | | | | | | | | | | - Vincent Dore
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | | |
Collapse
|
46
|
Dore V, Bourgeat P, Cummins TL, Raniga P, Williams S, Amadoru S, MacLean C, Hinton F, Shepherd C, Halliday GM, Leyton CE, Hodges JR, Ames D, Martins RN, Masters CL, Fripp J, Salvado O, Villemagne VL, Rowe C. IC‐P‐008: VISUAL ASSESSMENT OF β‐AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Vincent Dore
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
- Austin HealthMelbourneAustralia
| | - Pierrick Bourgeat
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Tia L. Cummins
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Parnesh Raniga
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | | | | | | | - Fairlie Hinton
- The Florey Institute of Neuroscience and Mental HealthParkvilleAustralia
| | | | - Glenda M. Halliday
- Neuroscience Research Australia and University of New South WalesSydneyAustralia
| | | | - John R. Hodges
- Australian Research Council Centre of Excellence in Cognition and its DisordersSydneyAustralia
| | - David Ames
- The University of MelbourneParkvilleAustralia
| | | | - Colin L. Masters
- Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Jurgen Fripp
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Olivier Salvado
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | | | - Christopher Rowe
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| |
Collapse
|
47
|
Doecke JD, Laws SM, Gardener SL, Porter T, Ames D, Maruff P, Masters CL, Rowe C, Salvado O, Martins RN, Rainey-Smith SR. P3‐097: CARDIOVASCULAR RISK FACTORS MODULATE ALZHEIMER'S DISEASE RISK VIA SNPS IN THE
CYP11B2
,
PPAP2B
AND
APP
GENES. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
| | | | | | - Tenielle Porter
- Cooperative Research Centre for Mental HealthMelbourneAustralia
| | | | - Paul Maruff
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Christopher Rowe
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | | | | | | |
Collapse
|
48
|
Fernando WM, Sohrabi H, Doecke JD, Rainey-Smith SR, Savage G, Villemagne VL, Maruff P, Burnham SC, Gardener SL, Weinborn M, Rowe CC, Salvado O, Ames D, Masters CL, Martins RN. P3‐620: INCREASED PROTEIN AND FIBRE INTAKE IS ASSOCIATED WITH HIGHER PERFORMANCE IN THE AIBL PACC SCORE IN COGNITIVELY NORMAL ADULTS: AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE (AIBL) STUDY. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
| | | | - James D. Doecke
- Commonwealth Scientific and Industrial Research OrganisationPreventative Health FlagshipHerstonAustralia
| | | | | | | | - Paul Maruff
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Samantha C. Burnham
- Commonwealth Scientific and Industrial Research OrganisationMelbourneAustralia
| | | | | | | | - Olivier Salvado
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - David Ames
- The University of MelbourneParkvilleAustralia
| | - Colin L. Masters
- Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Ralph N. Martins
- Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)PerthAustralia
| | | |
Collapse
|
49
|
Yassi N, Hilal S, Xia Y, Lim Y, Kuijf HJ, Fowler C, Yates PA, Chen CP, Rowe C, Villemagne VL, Salvado O, Desmond PM, Masters CL. O2‐13‐05: COMORBIDITY OF CEREBROVASCULAR DISEASE AND AMYLOID‐β AND ITS INFLUENCE ON RATES OF COGNITIVE DECLINE AND NEURODEGENERATION. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Nawaf Yassi
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
- University of MelbourneMelbourneAustralia
| | - Saima Hilal
- Erasmus University Medical CenterRotterdamNetherlands
| | - Ying Xia
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Yen Lim
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | - Hugo J. Kuijf
- Image Sciences InstituteUniversity Medical Center UtrechtUtrechtNetherlands
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | | | - Christopher P. Chen
- Yong Loo Lin School of MedicineNational University of SingaporeSingaporeSingapore
| | - Christopher Rowe
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | | | - Olivier Salvado
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | | | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| |
Collapse
|
50
|
Lim YY, Williamson R, Laws SM, Villemagne VL, Bourgeat P, Fowler C, Rainey-Smith S, Salvado O, Martins RN, Rowe CC, Masters CL, Maruff P. Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. J Alzheimers Dis 2018; 58:1293-1302. [PMID: 28550258 DOI: 10.3233/jad-170072] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND The association between the apolipoprotein E (APOE) ɛ4 allele and high risk of developing Alzheimer's disease (AD) dementia before the age of 80 has been recognized for over 30 years. However, the timing and mode of action of APOE is not understood, nor has there been a detailed analysis of the effect of APOE genotype on memory, hippocampal volume, and amyloid-β (Aβ) levels in cognitively normal adults. OBJECTIVE Examine the effect of APOE allelic genotype on the relationship between Aβ levels, hippocampal volume, and memory in cognitively normal adults. METHODS This is a cross-sectional study of 989 cognitively normal older adults enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, all of whom underwent APOE genotyping and memory assessment. A subset of this group underwent PET neuroimaging for Aβ (n = 585) and MRI for hippocampal volume (n = 303). RESULTS APOEɛ4 homozygotes (ɛ4/ɛ4) showed significantly worse episodic memory and higher Aβ levels than ɛ4 heterozygotes. The relationship between increasing Aβ levels and worse episodic memory was significant for ɛ3 homozygotes (ɛ3/ɛ3), ɛ4 heterozygotes, and strongest for ɛ4 homozygotes. There were no differences in hippocampal volume between APOE groups; the relationship between smaller hippocampal volume and worse episodic memory was significant only for ɛ4 homozygotes. CONCLUSION APOE acts in a co-dominant fashion on Aβ levels, episodic memory, and hippocampal volume in cognitively normal older adults. APOEɛ4 is central to the events that lead to AD in cognitively normal older adults, likely through a quantitative role in the disruption of Aβ clearance.
Collapse
Affiliation(s)
- Yen Ying Lim
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Robert Williamson
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Simon M Laws
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia.,Co-operative Research Centre for Mental Health, http://www.mentalhealthcrc.com.,School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia
| | - Pierrick Bourgeat
- CSIRO Preventative Health National Research Flagship, Australian e-Health Research Centre-BiaMedIA, Brisbane, Queensland, Australia
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Olivier Salvado
- CSIRO Preventative Health National Research Flagship, Australian e-Health Research Centre-BiaMedIA, Brisbane, Queensland, Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia
| | - Christopher C Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Cogstate Ltd., Melbourne, VIC, Australia
| | | |
Collapse
|